OncoMatch/Clinical Trials/NCT04098744
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Is NCT04098744 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Artesunate vaginal insert for cin 2/3.
Treatment: Artesunate vaginal insert — This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: HPV any genotype
Any HPV genotype detectable by DNA test/HPV genotyping
Disease stage
Required: Stage CIN2, CIN3, CIN2/3
Excluded: Stage CERVICAL ADENOCARCINOMA IN SITU
Grade: high grade
cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Gynecologic Oncology · Fort Myers, Florida
- University of Michigan · Ann Arbor, Michigan
- Cleveland Clinic Fairview Hospital · Cleveland, Ohio
- Cleveland Clinic Foundation · Cleveland, Ohio
- Hillcrest Hospital · Mayfield Heights, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify